Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $434,000 with net income of −$25M.
Q2 2026 key financials · XBRL
- Revenue
- $434,000
- +8.2% QoQ
- Net income
- −$25M
- −28.6% YoY · −32.7% QoQ
- Operating margin
- -5823.0%
- EPS (diluted)
- −$0.36
- −24.1% YoY · −33.3% QoQ
Source: XBRL data from the PULSE BIOSCIENCES, INC. (PLSE) Q2 2026 10-Q on SEC EDGAR. USD.
PULSE BIOSCIENCES, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue, margins, profitability, cash flow, and segment performance figures absent from provided excerpt
- February 2026 ATM: $46.8M net proceeds from 1,919,821 shares issued
- Capital allocation shifted toward electrophysiology, reducing cardiac surgery and Vybrance sales investments
- Cardiac catheter pivotal study: more than half of at least 164 evaluable patients enrolled
- Near-term headwinds: FDA PMA approval required before U.S. cardiac commercialization and continued financing needs
Risk Factors
- Additional capital needs, intensified by Middle East and Ukraine conflicts and rising tariffs, may force scaled-back operations
- Vybrance System adoption remains slow among surgeons, citing reimbursement uncertainty and limited long-term clinical data
- FDA changes and trade tariffs may increase operating costs and delay regulatory timelines
- Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic possess greater resources and established customer relationships
- Revenue dependence on the nPulse System and NPS platform concentrates commercial and product-development risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PULSE BIOSCIENCES, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.